CD38 Modulating Antibody Solid Tumor Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD38 antibodies for cancer treatment have limited efficacy in solid tumors due to low CD38 expression on tumor cells and associated immune cells, necessitating the development of antibodies with combined agonistic and modulating properties for enhanced immune activation and targeted cell killing.
Innovation Solution
Development of CD38 Modulating Antibody Agents that specifically bind to human CD38, modulating its activity and downstream effects, including antibodies like aCD38-a-323, aCD38-b-329, aCD38-b-348, and aCD38-a-327, which exhibit reduced complement-dependent cytotoxicity, induce immune effector cell activation, and demonstrate enhanced ADCC activity, while also modulating CD38 enzymatic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-CD38 antibodies are used for targeted cell killing, then tumor cell killing activity is improved, but efficacy in solid tumors is limited due to low CD38 expression on tumor cells
Solution Approach 1:
The patent applies multi-functionality by designing anti-CD38 antibodies that simultaneously perform multiple functions: (1) bind to CD38 on tumor cells for targeted killing, (2) activate immune effector cells through Fc region engagement, and (3) modulate CD38 enzymatic activity to reduce immunosuppression. This allows the antibody to be effective across different tumor types regardless of CD38 expression levels on tumor cells themselves, as immune cell activation provides an alternative mechanism for solid tumor efficacy
2Reliability
If CD38-targeting therapies are developed as CD38 antagonists or inhibitors, then enzymatic activity modulation is improved, but immune activation is insufficient
Solution Approach 1:
The patent combines two previously separate therapeutic approaches into a single antibody molecule: (1) CD38 enzymatic inhibition through antigen binding, and (2) immune activation through Fc region engagement with immune effector cells. The merged antibody simultaneously modulates CD38 enzymatic activity and activates immune responses, providing both mechanisms of action in one therapeutic agent
3Measurement precision
If anti-CD38 antibodies are designed for direct tumor cell killing, then specificity to CD38-expressing cells is improved, but activity is restricted to tumors with high CD38 expression
Solution Approach 1:
The patent introduces immune effector cells as intermediaries in the therapeutic mechanism. Instead of requiring direct antibody-tumor cell killing, the antibody binds to CD38 and uses immune effector cells as mediators to deliver the therapeutic effect through Fc region engagement. This intermediary mechanism allows the antibody to be effective in tumors with low CD38 expression, as the immune activation pathway provides an alternative route to tumor cell killing while maintaining specificity through CD38 binding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively activate immune cells, induce cytokine secretion, and exhibit reduced CDC activity, providing a therapeutic advantage in treating both hematological and solid cancers by targeting CD38-expressing cells with enhanced immune response and reduced toxicity.
Implementation Method 1
antibodies or antigen-binding fragments that specifically bind to CD38, and particularly to human CD38, in many embodiments to a site in the human CD38 extracellular domain
Implementation Method 2
exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) activity against CD38+ target cells
Implementation Method 3
CD38 is a type II membrane receptor glycoprotein having enzymatic activities, in particular as an important ADP-ribosyl cyclase that produces cyclic adenosine diphosphate ribose (cADPR) from nicotinamide adenine dinucleotide
Data Source
AI summary
The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.